Review



pten  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC pten
    Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
    Pten, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 9957 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pten/product/ATCC
    Average 99 stars, based on 9957 article reviews
    pten - by Bioz Stars, 2026-05
    99/100 stars

    Images

    1) Product Images from "Repurposing drugs for treating the neurobehavioral manifestations of PTEN hamartoma tumor syndrome"

    Article Title: Repurposing drugs for treating the neurobehavioral manifestations of PTEN hamartoma tumor syndrome

    Journal: iScience

    doi: 10.1016/j.isci.2026.115428

    Compound screening in SH-SY5Y PTEN −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
    Figure Legend Snippet: Compound screening in SH-SY5Y PTEN −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.

    Techniques Used: Activity Assay, Phospho-proteomics, Generated, Control, Labeling



    Similar Products

    pten  (ATCC)
    99
    ATCC pten
    Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
    Pten, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pten/product/ATCC
    Average 99 stars, based on 1 article reviews
    pten - by Bioz Stars, 2026-05
    99/100 stars
    		  Buy from Supplier
    anti pten  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc anti pten
    Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
    Anti Pten, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pten/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    anti pten - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    pten 588  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc pten 588
    Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
    Pten 588, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pten 588/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    pten 588 - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    rabbit anti pten  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc rabbit anti pten
    Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
    Rabbit Anti Pten, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti pten/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    rabbit anti pten - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    anti pten induced putative kinase 1  (Proteintech)
    96
    Proteintech anti pten induced putative kinase 1
    Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
    Anti Pten Induced Putative Kinase 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pten induced putative kinase 1/product/Proteintech
    Average 96 stars, based on 1 article reviews
    anti pten induced putative kinase 1 - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    pten cap8 cells  (ATCC)
    94
    ATCC pten cap8 cells
    Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
    Pten Cap8 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pten cap8 cells/product/ATCC
    Average 94 stars, based on 1 article reviews
    pten cap8 cells - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    mcherry fkbp pten  (Addgene inc)
    92
    Addgene inc mcherry fkbp pten
    Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
    Mcherry Fkbp Pten, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mcherry fkbp pten/product/Addgene inc
    Average 92 stars, based on 1 article reviews
    mcherry fkbp pten - by Bioz Stars, 2026-05
    92/100 stars
    		  Buy from Supplier
    gene exp pten hs02621230 s1  (Thermo Fisher)
    99
    Thermo Fisher gene exp pten hs02621230 s1
    Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
    Gene Exp Pten Hs02621230 S1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp pten hs02621230 s1/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    gene exp pten hs02621230 s1 - by Bioz Stars, 2026-05
    99/100 stars
    		  Buy from Supplier
    pten cell signaling technology  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc pten cell signaling technology
    Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
    Pten Cell Signaling Technology, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pten cell signaling technology/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    pten cell signaling technology - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Compound screening in SH-SY5Y PTEN −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.

    Journal: iScience

    Article Title: Repurposing drugs for treating the neurobehavioral manifestations of PTEN hamartoma tumor syndrome

    doi: 10.1016/j.isci.2026.115428

    Figure Lengend Snippet: Compound screening in SH-SY5Y PTEN −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.

    Article Snippet: Knockout of PTEN in the SH-SY5Y line (ATCC, CRL-2266) was generated using CRISPR technology.

    Techniques: Activity Assay, Phospho-proteomics, Generated, Control, Labeling